Actuate Therapeutics, Inc. Launches Expanded Research Program To Test Elraglusib In Combination With Emerging RAS-Targeted Therapies

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for difficult-to-treat cancers through inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced the launch of an expanded research initiative to evaluate combinations of its clinical-stage GSK-3β inhibitor, elraglusib, with emerging RAS-targeted therapies. 

The company noted that although RAS-targeted drugs have made encouraging progress in recent years, many patients still face barriers such as adaptive resistance mechanisms and pathway reactivation, issues that have been widely discussed in recent scientific literature (Dilly et al., Cancer Discovery 2024). These challenges have underscored the need for combination strategies that can strengthen and extend the therapeutic impact of RAS inhibition.

Actuate believes that GSK-3β inhibition may play a critical complementary role by suppressing downstream survival signaling and resistance-associated pathways, including NF-κB–mediated signaling, MYC-driven transcriptional programs, metabolic adaptation, oxidative stress buffering, and immune suppression within the tumor microenvironment. 

The company also highlighted the particular difficulty of treating RAS-mutant tumors especially pancreatic cancer which are often considered immunologically resistant. Preclinical research suggests that inhibiting GSK-3β can help counter this resistance by enhancing antigen presentation, activating T cells and NK cells, and reducing populations of exhausted T cells. By targeting both intrinsic tumor survival pathways and the surrounding immune landscape, Actuate believes that combining elraglusib with RAS inhibitors may create a multi-modal therapeutic approach that can overcome resistance and broaden clinical benefit in RAS-driven cancers.

Elraglusib is a highly selective, best-in-class GSK-3β inhibitor with potential application across several cancer types, including pancreatic cancer, melanoma, colorectal cancer, and sarcoma. More than 500 patients have been treated with the investigational therapy, and it is currently being studied in a Phase 2 clinical trial in metastatic pancreatic ductal adenocarcinoma (mPDAC). Actuate’s combination strategy aims to block tumor proliferation through RAS inhibition while simultaneously disrupting tumor survival pathways through GSK-3β inhibition, a dual approach the company believes may amplify apoptotic signaling beyond what RAS inhibitors can achieve alone.

The combination development program will include in-vitro studies using tumor models characterized by RAS resistance, in-vivo studies focused on tumor regression and survival outcomes, and translational biomarker analysis. Actuate expects to share initial data from the program in the second quarter of 2026, followed by additional results in the second half of the year. 

The company emphasized that while next-generation RAS inhibitors have shown meaningful promise, emerging research continues to support the need for combination strategies to maximize their effectiveness (Long et al., Cancer Research 2026). By targeting GSK-3β, a central regulator of tumor survival, Actuate believes elraglusib could help enhance both the depth and durability of responses to RAS-targeted therapies. The company is moving this work forward in collaboration with leading academic researchers and potential industry partners, positioning elraglusib as a candidate for future foundational treatment approaches in RAS-driven cancers.